Nimotuzumab

also known as hR3 · Nimo · OSAG101 · TheraCIM h-R3 · NTZ · TheraCIM · Theraloc

Developed for: nasopharyngeal carcinoma · esophageal squamous cell carcinoma · head and neck squamous cell carcinoma · non-small cell lung carcinoma · malignant pancreatic neoplasm · cervical cancer · esophageal cancer · colorectal cancer
+37 more
· carcinoma of esophagus · cervical squamous cell carcinoma · gastric cancer · gastroesophageal cancer · head and neck cancer · adenocarcinoma · cancer · cervical adenosquamous carcinoma · diffuse intrinsic pontine glioma · gastric neoplasm · oral cavity squamous cell carcinoma · pancreas disorder · adult glioblastoma · anal canal squamous cell carcinoma · bladder transitional cell carcinoma · breast cancer · cancer of unknown primary site · carcinoma · cervical carcinoma · childhood brain stem neoplasm · esophageal disorder · gastroesophageal adenocarcinoma · glioblastoma · glioma · hepatocellular carcinoma · hypopharynx squamous cell carcinoma · lung cancer · lung carcinoma · malignant glioma · neoplastic meningitis · oropharyngeal carcinoma · oropharynx squamous cell carcinoma · pancreatic ductal adenocarcinoma · pancreatic neoplasm · pancreatic neuroendocrine neoplasm · penile cancer · squamous cell carcinoma
Investigated by: Biotech Pharmaceutical Co., Ltd. · Sun Yat-sen University · Fudan University · Tianjin Medical University Cancer Institute and Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Peking University
+105 more
· Chinese Academy of Medical Sciences · YM BioSciences · Zhejiang Cancer Hospital · Zhejiang University · Eurofarma Laboratorios S.A. · Fujian Cancer Hospital · The First Affiliated Hospital with Nanjing Medical University · CIMYM BioSciences · Chinese PLA General Hospital · Jiangxi Provincial Cancer Hospital · Peking Union Medical College Hospital · Peking University First Hospital · Air Force Military Medical University, China · Hangzhou Cancer Hospital · National Institute of Cancerology · Peking University Third Hospital · People's Hospital of Guangxi Zhuang Autonomous Region · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · The First Affiliated Hospital of Xiamen University · The First Affiliated Hospital of Zhengzhou University · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Affiliated Cancer Hospital of Shantou University Medical College · Affiliated Hospital of Hebei University · Baotou Cancer Hospital · Beijing Army General Hospital · Beijing Hospital · Centro de Immunologia Molecular, Cuba · Chinese Thoracic Oncology Group · Cinda Biopharmaceutical (Suzhou) Co., Ltd. · Daiichi Sankyo · Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany · Dr. Te Vuong · Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany · El Kendi Pharmaceuticals Manufacturing Company · Eye & ENT Hospital of Fudan University · First Affiliated Hospital, Sun Yat-Sen University · First People's Hospital of Foshan · Fourth Affiliated Hospital of Guangxi Medical University · Fujian Medical University Union Hospital · Fujian Province Tumor Hospital · Guangdong Association of Clinical Trials · Guangdong Provincial People's Hospital · Guangxi Medical University · Guangzhou Medical University · Guilin Medical University, China · Guiyang Medical University · Hebei Medical University Fourth Hospital · Heinrich-Heine University, Duesseldorf · Henan Cancer Hospital · Hubei Cancer Hospital · Hui Bu · Hunan Provincial Cancer Hospital · Innogene Kalbiotech Pte. Ltd · Johann Wolfgang Goethe University Hospital · Kuhnil Pharmaceutical Co., Ltd. · Laboratorios PiSA · Lei Li · Lepu Biopharma Co., Ltd. · LiuZhou People's Hospital · Ming-Yuan Chen · NanJing PLA 81 Hospital · National Cancer Centre, Singapore · National Heart Institute, Mexico · Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany · Oncoscience AG · Peking University Cancer Hospital & Institute · People's Hospital of Baise · RenJi Hospital · Roswell Park Cancer Institute · Samsung Medical Center · Second Affiliated Hospital of Guangzhou Medical University · Shandong Cancer Hospital and Institute · Shanghai Changzheng Hospital · Shanghai Chest Hospital · all 111 on the full record

Trials 143 · started per year

today

200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT07053735	Jun 2025 → Jun 2027 expected	bladder transitional cell carcinoma	Peking University First Hospital	Not yet recruiting	No outcome recorded
Phase 1	NCT03554889	Aug 2018 → Mar 2019	cancer of unknown primary site	Hangzhou Cancer Hospital	Unknown	No outcome recorded
Phase 1	NCT02947386	Jun 2017 → Apr 2021	non-small cell lung carcinoma	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1	NCT02395068	Nov 2012 → Nov 2014	cancer	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT00985998	Sep 2009 → Aug 2015	non-small cell lung carcinoma	Biotech Pharmaceutical Co., Ltd.	Withdrawn	No outcome recorded
Phase 1	NCT00950417	Jul 2009 → Jul 2010	esophageal cancer	Biotech Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT00369252	Jun 2005 → ?	—	YM BioSciences	Completed	No outcome recorded
Phase 1/27 trials
Phase 1/2	NCT07105592	May 2025 → May 2027 expected	head and neck squamous cell carcinoma	Fudan University	Recruiting	No outcome recorded
Phase 1/2	NCT06773130	Feb 2025 → Aug 2026 overdue	pancreatic ductal adenocarcinoma	West China Hospital	Active not recruiting	No outcome recorded
Phase 1/2	NCT01993784	Aug 2013 → Mar 2014	esophageal squamous cell carcinoma	Peking University	Unknown	No outcome recorded
Phase 1/2	NCT01861223	May 2013 → May 2015	non-small cell lung carcinoma	Samsung Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT05278728	Jul 2009 → Aug 2013	colorectal cancer	Biotech Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1/2	NCT00369447	Mar 2009 → Jun 2011	non-small cell lung carcinoma	YM BioSciences	Terminated	No outcome recorded
Phase 1/2	NCT02095119	Jul 2008 → Dec 2013	cervical cancer	National Institute of Cancerology	Completed	No outcome recorded
Phase 294 trials
Phase 2	NCT07707973	Jul 2026 → Jan 2028 expected	malignant glioma	Tianjin First Central Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07601737	Apr 2026 → Apr 2028 expected	head and neck squamous cell carcinoma	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT07457528	Mar 2026 → Jun 2027 expected	esophageal squamous cell carcinoma	Tianjin Medical University Cancer Institute and Hospital	Recruiting	No outcome recorded
Phase 2	NCT07446270	Mar 2026 → Oct 2027 expected	colorectal cancer	Chinese PLA General Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07240766	Feb 2026 → May 2027 expected	adenocarcinoma	Zhejiang University	Recruiting	No outcome recorded
Phase 2	NCT07310771	Jan 2026 → Jul 2027 expected	head and neck squamous cell carcinoma	Fujian Cancer Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07354984	Jan 2026 → Dec 2029 expected	head and neck squamous cell carcinoma	Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 2	NCT07277452	Dec 2025 → Dec 2028 expected	malignant pancreatic neoplasm	The First Affiliated Hospital with Nanjing Medical University	Not yet recruiting	No outcome recorded
Phase 2	NCT07386704	Dec 2025 → Dec 2026 expected	malignant pancreatic neoplasm	Peking University First Hospital	Enrolling by invitation	No outcome recorded
Phase 2	NCT07353723	Nov 2025 → Nov 2026 expected	head and neck cancer	Tang-Du Hospital	Recruiting	No outcome recorded
Phase 2	NCT07312578	Nov 2025 → Nov 2027 expected	esophageal squamous cell carcinoma	Peking University	Enrolling by invitation	No outcome recorded
Phase 2	NCT07101744	Oct 2025 → Jul 2028 expected	nasopharyngeal carcinoma	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 2	NCT07070479	Jun 2025 → Jan 2027 expected	nasopharyngeal carcinoma	Ming-Yuan Chen	Recruiting	No outcome recorded
Phase 2	NCT06912711	May 2025 → Apr 2029 expected	nasopharyngeal carcinoma	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 2	NCT06938503	Apr 2025 → Apr 2028 expected	malignant pancreatic neoplasm	Tianjin Medical University Cancer Institute and Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06770452	Mar 2025 → Feb 2027 expected	carcinoma	Zhejiang University	Recruiting	No outcome recorded
Phase 2	NCT06722911	Nov 2024 → Sep 2028 expected	pancreas disorder	Zhejiang Provincial People's Hospital	Recruiting	No outcome recorded
Phase 2	NCT06676722	Nov 2024 → Dec 2026 expected	nasopharyngeal carcinoma	The First Affiliated Hospital of Xiamen University	Recruiting	No outcome recorded
Phase 2	NCT06509009	Aug 2024 → May 2026 overdue	nasopharyngeal carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recruiting	No outcome recorded
Phase 2	NCT06490341	Jul 2024 → Jul 2026 overdue	nasopharyngeal carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 2	NCT06422156	Jun 2024 → Jun 2026	malignant pancreatic neoplasm	Peking University Third Hospital	Unknown	No outcome recorded
Phase 2	NCT06429904	May 2024 → May 2027 expected	pancreatic neoplasm	Peking Union Medical College Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT06988956	Mar 2024 → Apr 2027 expected	esophageal squamous cell carcinoma	The First Affiliated Hospital with Nanjing Medical University	Recruiting	No outcome recorded
Phase 2	NCT06259721	Feb 2024 → Feb 2026 overdue	nasopharyngeal carcinoma	Jiangxi Provincial Cancer Hospital	Recruiting	No outcome recorded
Phase 2	NCT06389760	Oct 2023 → Sep 2026 expected	malignant pancreatic neoplasm	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Recruiting	No outcome recorded
Phase 2	NCT06039891	Oct 2023 → Oct 2024 overdue	cervical cancer	Peking Union Medical College Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06413017	Aug 2023 → Jul 2025	hepatocellular carcinoma	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
Phase 2	NCT05803915	May 2023 → Sep 2024	oral cavity squamous cell carcinoma	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 2	NCT06405685	Apr 2023 → Oct 2025	malignant pancreatic neoplasm	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
Phase 2	NCT06718205	Mar 2023 → Sep 2025 overdue	esophageal cancer	The First Affiliated Hospital of Zhengzhou University	Recruiting	No outcome recorded
Phase 2	NCT06429839	Mar 2023 → Dec 2025 overdue	esophageal cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recruiting	No outcome recorded
Phase 2	NCT06410651	Mar 2023 → Dec 2025 overdue	esophageal squamous cell carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recruiting	No outcome recorded
Phase 2	NCT05606263	Nov 2022 → Nov 2023	cervical cancer	Xi'an Jiaotong University	Unknown	No outcome recorded
Phase 2	NCT05351762	Jul 2022 → May 2024	head and neck squamous cell carcinoma	Xijing Hospital	Unknown	No outcome recorded
Phase 2	NCT06404840	May 2022 → Mar 2025	malignant pancreatic neoplasm	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
Phase 2	NCT05316480	May 2022 → Apr 2025 overdue	pancreatic neuroendocrine neoplasm	Fudan University	Not yet recruiting	No outcome recorded
Phase 2	NCT05508347	Apr 2022 → Oct 2025 overdue	nasopharyngeal carcinoma	Sichuan Cancer Hospital and Research Institute	Recruiting	No outcome recorded
Phase 2	NCT03766178	Sep 2021 → Dec 2022	esophageal squamous cell carcinoma	The First Affiliated Hospital of Zhengzhou University	Unknown	No outcome recorded
Phase 2	NCT05024019	Aug 2021 → Aug 2025	head and neck squamous cell carcinoma	Eye & ENT Hospital of Fudan University	Unknown	No outcome recorded
Phase 2	NCT06771596	May 2021 → Jul 2025 overdue	cervical squamous cell carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Active not recruiting	No outcome recorded
Phase 2	NCT04882462	May → Nov 2021	head and neck squamous cell carcinoma	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 2	NCT04833205	Apr 2021 → Apr 2022	lung cancer, neoplastic meningitis	Hui Bu	Unknown	No outcome recorded
Phase 2	NCT04664244	Dec 2020 → Dec 2023	cervical carcinoma	Lei Li	Unknown	No outcome recorded
Phase 2	NCT06048913	Dec 2020 → Jan 2025	carcinoma of esophagus	The First Affiliated Hospital with Nanjing Medical University	Completed	No outcome recorded
Phase 2	NCT04475016	Aug 2020 → May 2022	penile cancer	Sun Yat-sen University	Completed	No outcome recorded
Phase 2	NCT04367909	Jun 2020 → Dec 2021	oral cavity squamous cell carcinoma	Xin-Hua Xu	Unknown	No outcome recorded
Phase 2	NCT04223024	Jan 2020 → Aug 2024 overdue	nasopharyngeal carcinoma	Sun Yat-sen University	Active not recruiting	No outcome recorded
Phase 2	NCT04207918	Nov 2019 → Dec 2022	esophageal squamous cell carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT04136600	Jul 2019 → Aug 2021	gastric cancer	Shanghai Changzheng Hospital	Unknown	No outcome recorded
Phase 2	NCT03915132	May 2019 → May 2020	nasopharyngeal carcinoma	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT03708822	Oct 2018 → Jul 2022	nasopharyngeal carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 2	NCT03574402	Jul 2018 → Dec 2022	non-small cell lung carcinoma	Guangdong Association of Clinical Trials	Unknown	No outcome recorded
Phase 2	NCT03557112	Jun 2018 → Jun 2021	nasopharyngeal carcinoma	Guiyang Medical University	Unknown	No outcome recorded
Phase 2	NCT03469531	Mar 2018 → Mar 2021	cervical adenosquamous carcinoma, uterine cervix carcinoma in situ	Zhujiang Hospital	Unknown	No outcome recorded
Phase 2	NCT03025958	Mar 2017 → Nov 2018	nasopharyngeal carcinoma	Zhejiang Cancer Hospital	Completed	No outcome recorded
Phase 2	NCT02858206	Jun 2016 → Nov 2019	carcinoma of esophagus	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT04508829	Jan 2016 → Dec 2023	oropharyngeal carcinoma	Fudan University	Unknown	No outcome recorded
Phase 2	NCT04508816	Jan 2016 → Oct 2020	nasopharyngeal carcinoma	Fudan University	Completed	No outcome recorded
Phase 2	NCT02672241	Jan 2016 → Aug 2019	childhood brain stem neoplasm	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 2	NCT02705612	Sep 2015 → Sep 2016	cervical cancer	Air Force Military Medical University, China	Unknown	No outcome recorded
Phase 2	NCT02577341	Aug 2015 → Jun 2020	non-small cell lung carcinoma	Sun Yat-sen University	Completed	No outcome recorded
Phase 2	NCT03400592	Jun 2015 → Jun 2018	gastric neoplasm	Peking University	Unknown	No outcome recorded
Phase 2	NCT02428764	Apr 2015 → Oct 2025	lung carcinoma	Sun Yat-sen University	Withdrawn	No outcome recorded
Phase 2	NCT03666221	Nov 2014 → Apr 2020	nasopharyngeal carcinoma	Fujian Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT02034968	Feb 2014 → Jan 2016	esophageal squamous cell carcinoma	Zhejiang University	Withdrawn	No outcome recorded
Phase 2	NCT02041819	Feb 2014 → Jan 2016	esophageal squamous cell carcinoma	Zhejiang University	Withdrawn	No outcome recorded
Phase 2	NCT02011594	Jan 2014 → Jan 2015	esophageal squamous cell carcinoma	Zhejiang University	Withdrawn	No outcome recorded
Phase 2	NCT01939054	Sep 2013 → Sep 2015	breast cancer	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01899118	Apr 2013 → Apr 2016	—	Zhejiang Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT02039791	Jan 2013 → Jun 2016	cervical cancer	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT01688700	Sep 2012 → Sep 2013	esophageal squamous cell carcinoma	Zhejiang Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT01616849	May 2012 → Jul 2015	nasopharyngeal carcinoma	Sun Yat-sen University	Completed	No outcome recorded
Phase 2	NCT01516996	Mar 2012 → Sep 2013	hypopharynx squamous cell carcinoma, oropharynx squamous cell carcinoma	The Second People's Hospital of Sichuan	Unknown	No outcome recorded
Phase 2	NCT01382745	Jan 2012 → Sep 2021	anal canal squamous cell carcinoma	Dr. Te Vuong	Terminated	No outcome recorded
Phase 2	NCT01498562	Dec 2011 → Jun 2014	non-small cell lung carcinoma	Yonsei University	Completed	No outcome recorded
Phase 2	NCT01486992	Nov 2011 → Nov 2012	carcinoma of esophagus	Peking University	Unknown	No outcome recorded
Phase 2	NCT01463605	Jun 2011 → Dec 2016	esophageal cancer	Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT01393184	Mar 2011 → Feb 2013	head and neck squamous cell carcinoma	Peking University	Unknown	No outcome recorded
Phase 2	NCT01145170	Mar 2011 → Jun 2014	glioma	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 2	NCT01336049	Mar → Dec 2011	esophageal squamous cell carcinoma	Peking University	Unknown	No outcome recorded
Phase 2	NCT01301612	Jan 2011 → Dec 2017	cervical adenosquamous carcinoma	Eurofarma Laboratorios S.A.	Withdrawn	No outcome recorded
Phase 2	NCT01232374	Sep 2010 → Oct 2015	squamous cell carcinoma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03388372	Aug 2010 → Mar 2017	glioblastoma	Biotech Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT01180166	May 2010 → Sep 2013	gastric cancer	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT02370849	Oct 2009 → Feb 2012	gastric neoplasm	Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT00983047	Aug 2009 → Aug 2015	non-small cell lung carcinoma	Biotech Pharmaceutical Co., Ltd.	Terminated	No outcome recorded
Phase 2	NCT00972465	Jun → Dec 2009	colorectal cancer	Peking University	Unknown	No outcome recorded
Phase 2	NCT00910117	May 2009 → Dec 2011	head and neck squamous cell carcinoma	Fudan University	Completed	No outcome recorded
Phase 2	NCT00872482	Apr 2009 → Jun 2011	non-small cell lung carcinoma	YM BioSciences	Terminated	No outcome recorded
Phase 2	NCT01425736	Jan 2009 → Jan 2011	head and neck squamous cell carcinoma	Wei Guo	Completed	No outcome recorded
Phase 2	NCT02591784	Nov 2008 → Dec 2011	esophageal disorder	Biotech Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT00702481	Apr 2008 → Sep 2019	head and neck cancer	National Cancer Centre, Singapore	Completed	No outcome recorded
Phase 2	NCT00600054	Oct 2007 → Mar 2010	diffuse intrinsic pontine glioma	YM BioSciences	Completed	No outcome recorded
Phase 2	NCT00493857	Jun 2007 → Aug 2008	colorectal cancer	YM BioSciences	Terminated	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT06409429	May 2024 → May 2027 expected	malignant pancreatic neoplasm	Tianjin Medical University Cancer Institute and Hospital	Not yet recruiting	No outcome recorded
Phase 2/3	NCT02272699	Nov 2014 → Dec 2020	esophageal squamous cell carcinoma	Peking University	Withdrawn	No outcome recorded
Phase 2/3	NCT01402180	Dec 2010 → Dec 2013	esophageal squamous cell carcinoma	Fudan University	Unknown	No outcome recorded
Phase 2/3	NCT01249352	Jan 2009 → Nov 2013	adenocarcinoma, esophageal cancer	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 322 trials
Phase 3	NCT07445048	Mar 2026 → Mar 2028 expected	head and neck squamous cell carcinoma	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Recruiting	No outcome recorded
Phase 3	NCT07333274	Jan 2026 → Jan 2028 expected	head and neck squamous cell carcinoma	Shandong Cancer Hospital and Institute	Recruiting	No outcome recorded
Phase 3	NCT05978050	Aug 2024 → Mar 2026 overdue	gastroesophageal adenocarcinoma	Biotech Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT06333821	Apr 2024 → Apr 2030 expected	cervical cancer	Biotech Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT06343116	Apr 2024 → Apr 2027 expected	colorectal cancer	Biotech Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT06026878	Sep 2023 → Sep 2025 overdue	nasopharyngeal carcinoma	Air Force Military Medical University, China	Recruiting	No outcome recorded
Phase 3	NCT05772208	Jan 2022 → Jan 2025 overdue	nasopharyngeal carcinoma	Fudan University	Recruiting	No outcome recorded
Phase 3	NCT04532229	Apr 2021 → Oct 2023	diffuse intrinsic pontine glioma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04456322	Aug 2020 → May 2024 overdue	nasopharyngeal carcinoma	Sun Yat-sen University	Active not recruiting	No outcome recorded
Phase 3	NCT03837808	Apr 2019 → Feb 2024	nasopharyngeal carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 3	NCT06781073	Jul 2017 → Nov 2024	cervical squamous cell carcinoma	Biotech Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02611700	Nov 2015 → Dec 2018	esophageal squamous cell carcinoma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03413579	Nov 2015 → Mar 2020	cervical cancer	El Kendi Pharmaceuticals Manufacturing Company	Completed	No outcome recorded
Phase 3	NCT02395016	Apr 2015 → Nov 2021	malignant pancreatic neoplasm	Biotech Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01345084	Nov 2013	head and neck squamous cell carcinoma	Eurofarma Laboratorios S.A.	Withdrawn	No outcome recorded
Phase 3	NCT01813253	May 2013 → Feb 2018	gastric cancer, gastroesophageal cancer	Kuhnil Pharmaceutical Co., Ltd.	Terminated	No outcome recorded
Phase 3	NCT02012062	Jul 2012 → Mar 2016	nasopharyngeal carcinoma	Fudan University	Completed	No outcome recorded
Phase 3	NCT02083211	Jul 2010 → May 2014	—	National Institute of Cancerology	Completed	No outcome recorded
Phase 3	NCT01074021	Oct 2009 → May 2016	nasopharyngeal carcinoma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT00753246	Aug 2007 → Jan 2012	adult glioblastoma	Oncoscience AG	Completed	No outcome recorded
Phase 3	NCT04821778	Jan 2002 → Dec 2030 expected	esophageal cancer, gastroesophageal cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recruiting	No outcome recorded
Phase 3	NCT04821843	Jan 2002 → Dec 2030 expected	esophageal cancer, gastroesophageal cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recruiting	No outcome recorded

Phase 43 trials
Phase 4	NCT06879691	May 2021 → Apr 2025 overdue	head and neck cancer	Biotech Pharmaceutical Co., Ltd.	Active not recruiting	No outcome recorded
Phase 4	NCT02945267	Sep 2016 → Dec 2018	pancreas disorder	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 4	NCT02293356	Aug 2015 → Dec 2017	nasopharyngeal carcinoma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase not applicable6 trials
—	NCT07388095	Feb 2026 → Feb 2027 expected	esophageal squamous cell carcinoma	Tianjin Medical University Cancer Institute and Hospital	Not yet recruiting	No outcome recorded
—	NCT06022276	Dec 2022 → Dec 2024	cancer	Tianjin Medical University Second Hospital	Unknown	No outcome recorded
—	NCT05717790	Dec 2022 → Nov 2024 overdue	nasopharyngeal carcinoma	Fourth Affiliated Hospital of Guangxi Medical University	Recruiting	No outcome recorded
—	NCT04678791	Dec 2020 → Dec 2024	cervical squamous cell carcinoma	Peking University Third Hospital	Unknown	No outcome recorded
—	NCT01393080	Mar 2011 → Dec 2016	non-small cell lung carcinoma	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
—	NCT02549261	Mar 2011 → Apr 2012	non-small cell lung carcinoma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded

Also used as a comparator or background therapy in 8 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 22 trials
Phase 2	NCT05355168 Background	Nov 2021 → Dec 2023	poisoning	Anhui Provincial Hospital	Completed	No outcome recorded
Phase 2	NCT03620032 Background	Nov 2015 → Nov 2022	diffuse intrinsic pontine glioma	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Unknown	No outcome recorded
Phase 2/32 trials
Phase 2/3	NCT07535567 Comparator	May 2026 → Dec 2028 expected	head and neck squamous cell carcinoma	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT00561990 Comparator	Sep 2007 → Jan 2013	malignant pancreatic neoplasm	Oncoscience AG	Completed	No outcome recorded
Phase 34 trials
Phase 3	NCT07706985 Comparator	Jul 2026 → Jul 2030 expected	nasopharyngeal carcinoma	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 3	NCT06561763 Background	Aug 2024 → Aug 2028 expected	nasopharyngeal carcinoma	Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 3	NCT02409186 Comparator	Mar 2015 → Dec 2017	—	Shandong Cancer Hospital and Institute	Unknown	No outcome recorded
Phase 3	NCT00957086 Comparator	Aug 2009 → Jan 2025	head and neck squamous cell carcinoma	National Cancer Centre, Singapore	Unknown	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2014-04-25	Daiichi Sankyo	Daiichi Sankyo Announces Discontinuation of Phase 3 Clinical Trial in Japan of Nimotuzumab (DE-766) in Lung Cancer daiichisankyo.com ↗
2013-04-25	Daiichi Sankyo	Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials daiichisankyo.com ↗
2006-08-01	Daiichi Sankyo	Daiichi Pharmaceutical to Develop and Market Anti-EGFr Drug Nimotuzumab in Japan daiichisankyo.com ↗

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 152 sources stand behind the page.

Field	Value	Cited text
Known as	Nimotuzumab	“Nimotuzumab is a humanized monoclonal antibody that can competitively inhibit the binding of endogenous ligands to EGFR, block the downstream signal transduction pathway...” NCT05508347 ↗ 150 “This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic...” NCT07101744 ↗ “Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.” NCT04508829 ↗ “Nimotuzumab (hR3) is an humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT01425736 ↗ “The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles” NCT05803915 ↗ “Toripalimab Combined With Nimotuzumab Induction therapy then surgery and Toripalimab Combined With Nimotuzumab adjuvant Therapy” NCT06912711 ↗ “Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression” NCT04136600 ↗ “[Docetaxel 75mg/m2 + Nimotuzumab 400mg + Pucotenlimab 200mg]” NCT07354984 ↗ “Nimotuzumab is a EGFR monoclonal antibody.” NCT06022276 ↗ “Nimotuzumab:400 mg” NCT07388095 ↗ NCT06718205 ↗ NCT02395068 ↗ NCT07457528 ↗ NCT06389760 ↗ NCT07310771 ↗ NCT06509009 ↗ NCT06333821 ↗ NCT01393080 ↗ NCT04508816 ↗ NCT02945267 ↗ NCT00972465 ↗ NCT00753246 ↗ NCT04882462 ↗ NCT06429839 ↗ NCT07445048 ↗ NCT02672241 ↗ NCT02293356 ↗ NCT06676722 ↗ NCT06429904 ↗ NCT03574402 ↗ NCT07053735 ↗ NCT00561990 ↗ NCT02011594 ↗ NCT06422156 ↗ NCT01393184 ↗ NCT07240766 ↗ NCT03413579 ↗ NCT03766178 ↗ NCT01180166 ↗ NCT04678791 ↗ NCT04821843 ↗ NCT01993784 ↗ NCT02034968 ↗ NCT01498562 ↗ NCT06413017 ↗ NCT07070479 ↗ NCT06048913 ↗ NCT00985998 ↗ NCT04223024 ↗ NCT05316480 ↗ NCT01345084 ↗ NCT06343116 ↗ NCT03620032 ↗ NCT01145170 ↗ NCT02041819 ↗ NCT01486992 ↗ NCT01336049 ↗ NCT04456322 ↗ NCT07706985 ↗ NCT01899118 ↗ NCT02039791 ↗ NCT02012062 ↗ NCT06770452 ↗ NCT02370849 ↗ NCT02591784 ↗ NCT07707973 ↗ NCT05717790 ↗ NCT06404840 ↗ NCT00957086 ↗ NCT03666221 ↗ NCT06879691 ↗ NCT00369252 ↗ NCT05606263 ↗ NCT00600054 ↗ NCT00872482 ↗ NCT06259721 ↗ NCT04821778 ↗ NCT01301612 ↗ NCT01382745 ↗ NCT02083211 ↗ NCT06409429 ↗ NCT07386704 ↗ NCT03837808 ↗ NCT03915132 ↗ NCT02395016 ↗ NCT03557112 ↗ NCT05772208 ↗ NCT03708822 ↗ NCT07333274 ↗ NCT01616849 ↗ NCT02858206 ↗ NCT05351762 ↗ NCT01516996 ↗ NCT01463605 ↗ NCT07277452 ↗ NCT06410651 ↗ NCT04664244 ↗ NCT00702481 ↗ NCT02549261 ↗ NCT07446270 ↗ NCT02272699 ↗ NCT01861223 ↗ NCT01074021 ↗ NCT05278728 ↗ NCT00369447 ↗ NCT06561763 ↗ NCT00493857 ↗ NCT05355168 ↗ NCT01402180 ↗ NCT06773130 ↗ NCT05024019 ↗ NCT01939054 ↗ NCT00910117 ↗ NCT02947386 ↗ NCT05978050 ↗ NCT04532229 ↗ NCT03388372 ↗ NCT06938503 ↗ NCT04833205 ↗ NCT03469531 ↗ NCT03554889 ↗ NCT07105592 ↗ NCT04367909 ↗ NCT01232374 ↗ NCT04475016 ↗ NCT07312578 ↗ NCT06490341 ↗ NCT03025958 ↗ NCT07535567 ↗ NCT02409186 ↗ NCT06771596 ↗ NCT01688700 ↗ NCT06781073 ↗ NCT00950417 ↗ NCT00983047 ↗ NCT04207918 ↗ NCT02428764 ↗ NCT01249352 ↗ NCT02705612 ↗ NCT07353723 ↗ NCT03400592 ↗ NCT06405685 ↗ NCT02577341 ↗ NCT07601737 ↗ NCT06988956 ↗ NCT02095119 ↗ NCT01813253 ↗ NCT06722911 ↗ NCT06039891 ↗ NCT06026878 ↗ NCT02611700 ↗
Known as	hR3	“Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease...” NCT04532229 ↗ 10 “Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT00985998 ↗ “Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT00950417 ↗ “Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT05316480 ↗ “Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT02549261 ↗ “Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT02591784 ↗ “Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT01393080 ↗ “Nimotuzumab (hR3) is an humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).” NCT01425736 ↗ “mAb Nimotuzumab hR3 will be administered endovenously in a 250 mL saline solution in 30 min. infusion ambulatory.” NCT02083211 ↗ “Nimotuzumab (OSAG101, hR3, Theraloc) is a humanized monoclonal antibody (mAb) that binds to the EGFR.” NCT00561990 ↗ “Nimotuzumab ( h-R3)” NCT03413579 ↗
Known as	Nimo	“of which 56 patients were added with Nimotuzumab (Nimo) and were divided into three groups” NCT05508347 ↗ 2 “Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT” NCT01393184 ↗ “nimotuzumab (nimo) will be administered” NCT06389760 ↗
Known as	NTZ	“cetuximab (CTX) or nimotuzumab (NTZ)” NCT04508816 ↗
Known as	OSAG101	“Patients randomly assigned to arm A will receive Nimotuzumab (OSAG 101) plus Temozolomide concomitant with standard radiotherapy.” NCT00753246 ↗ 1 “Nimotuzumab (OSAG101, hR3, Theraloc) is a humanized monoclonal antibody (mAb) that binds to the EGFR.” NCT00561990 ↗
Known as	TheraCIM	“Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma” NCT00600054 ↗
Known as	TheraCIM h-R3	“This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer.” NCT00369447 ↗ 1 “Nimotuzumab (TheraCIM h-R3)” NCT00369252 ↗
Known as	Theraloc	“Nimotuzumab (OSAG101, hR3, Theraloc) is a humanized monoclonal antibody (mAb) that binds to the EGFR.” NCT00561990 ↗
Action	Inhibit	“EGFR inhibition using Nimotuzumab” NCT00702481 ↗
Modality	Monoclonal antibody	“Nimotuzumab Humanized Monoclonal Antibody” NCT00493857 ↗
Route	Intravenous	“as a 30-min infusion” PMID 28961832 ↗ Oct 2017
Target	EGFR	“binds to the EGFR” NCT00561990 ↗